- Home
- DTSQ vs SKYE Comparison
DTSQ vs SKYE Comparison
Compare DTSQ & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSQ
- SKYE
- Stock Information
- Founded
- DTSQ 2022
- SKYE 2012
- Country
- DTSQ United States
- SKYE United States
- Employees
- DTSQ N/A
- SKYE N/A
- Industry
- DTSQ
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- DTSQ
- SKYE Health Care
- Exchange
- DTSQ NYSE
- SKYE Nasdaq
- Market Cap
- DTSQ 91.7M
- SKYE 73.4M
- IPO Year
- DTSQ 2024
- SKYE N/A
- Fundamental
- Price
- DTSQ $10.38
- SKYE $3.74
- Analyst Decision
- DTSQ
- SKYE Buy
- Analyst Count
- DTSQ 0
- SKYE 6
- Target Price
- DTSQ N/A
- SKYE $16.60
- AVG Volume (30 Days)
- DTSQ 538.0
- SKYE 2.0M
- Earning Date
- DTSQ 01-01-0001
- SKYE 08-08-2025
- Dividend Yield
- DTSQ N/A
- SKYE N/A
- EPS Growth
- DTSQ N/A
- SKYE N/A
- EPS
- DTSQ 0.28
- SKYE N/A
- Revenue
- DTSQ N/A
- SKYE N/A
- Revenue This Year
- DTSQ N/A
- SKYE N/A
- Revenue Next Year
- DTSQ N/A
- SKYE N/A
- P/E Ratio
- DTSQ $37.03
- SKYE N/A
- Revenue Growth
- DTSQ N/A
- SKYE N/A
- 52 Week Low
- DTSQ $9.96
- SKYE $1.14
- 52 Week High
- DTSQ $10.49
- SKYE $8.26
- Technical
- Relative Strength Index (RSI)
- DTSQ N/A
- SKYE 66.59
- Support Level
- DTSQ N/A
- SKYE $2.12
- Resistance Level
- DTSQ N/A
- SKYE $5.75
- Average True Range (ATR)
- DTSQ 0.00
- SKYE 0.55
- MACD
- DTSQ 0.00
- SKYE 0.17
- Stochastic Oscillator
- DTSQ 0.00
- SKYE 45.82
About DTSQ DT CLOUD STAR ACQUISITION CORP
DT Cloud Star Acquisition Corp is a blank check company.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.